Cargando…
Novel seizure outcomes in patients with Lennox‐Gastaut syndrome: Post hoc analysis of seizure‐free days in rufinamide Study 303
OBJECTIVE: Drug development for patients with Lennox‐Gastaut syndrome (LGS) is based on clinical trials that use drop seizure counts. However, such counts do not assess total seizure burden and affect a patient's quality of life (QoL). In this post hoc analysis, we evaluated two novel seizure e...
Autores principales: | Auvin, Stéphane, Williams, Betsy, McMurray, Rob, Kumar, Dinesh, Perdomo, Carlos, Malhotra, Manoj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546073/ https://www.ncbi.nlm.nih.gov/pubmed/31168494 http://dx.doi.org/10.1002/epi4.12314 |
Ejemplares similares
-
Treatment of Adults with Lennox–Gastaut Syndrome: Further Analysis of Efficacy and Safety/Tolerability of Rufinamide
por: McMurray, Rob, et al.
Publicado: (2016) -
Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide
por: Stafstrom, Carl E
Publicado: (2009) -
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
por: Kluger, Gerhard, et al.
Publicado: (2007) -
Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review
por: Balagura, Ganna, et al.
Publicado: (2020) -
Treating Lennox–Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide
por: Gresham, Jessica, et al.
Publicado: (2010)